Kezar Life Sciences (KZR) Debt to Equity (2021 - 2025)
Historic Debt to Equity for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $0.08.
- Kezar Life Sciences' Debt to Equity rose 473.61% to $0.08 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.08, marking a year-over-year increase of 473.61%. This contributed to the annual value of $0.09 for FY2024, which is 6455.81% up from last year.
- Latest data reveals that Kezar Life Sciences reported Debt to Equity of $0.08 as of Q3 2025, which was up 473.61% from $0.09 recorded in Q2 2025.
- Over the past 5 years, Kezar Life Sciences' Debt to Equity peaked at $0.09 during Q4 2024, and registered a low of $0.03 during Q2 2022.
- Its 5-year average for Debt to Equity is $0.06, with a median of $0.05 in 2021.
- In the last 5 years, Kezar Life Sciences' Debt to Equity plummeted by 2544.1% in 2022 and then surged by 6518.71% in 2024.
- Quarter analysis of 5 years shows Kezar Life Sciences' Debt to Equity stood at $0.05 in 2021, then dropped by 25.44% to $0.04 in 2022, then skyrocketed by 47.32% to $0.05 in 2023, then soared by 64.56% to $0.09 in 2024, then dropped by 9.23% to $0.08 in 2025.
- Its last three reported values are $0.08 in Q3 2025, $0.09 for Q2 2025, and $0.09 during Q1 2025.